Equities

Human Metabolome Technologies Inc

6090:TYO

Human Metabolome Technologies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)645.00
  • Today's Change-5.00 / -0.77%
  • Shares traded3.50k
  • 1 Year change-8.90%
  • Beta1.4451
Data delayed at least 20 minutes, as of May 02 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Human Metabolome Technologies, Inc. is a Japan-based biotechnology company developing capillary electrophoresis mass spectrometry (CE-MS) based metabolomics technologies and solutions. The Company operates in two segments. The Metabolome Analysis segment engages in the provision of analysis service that analyzes metabolomics of measurement samples and reports the results to customers. The Biomarker segment is engaged in the exploration of biomarkers, and the research and development of in vitro diagnostic drugs and diagnostic equipment.

  • Revenue in JPY (TTM)1.32bn
  • Net income in JPY282.64m
  • Incorporated2003
  • Employees57.00
  • Location
    Human Metabolome Technologies Inc246-2, Mizukami, KakuganjiTSURUOKA-SHI 997-0052JapanJPN
  • Phone+81 235251447
  • Fax+81 235251450
  • Websitehttps://humanmetabolome.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Modalis Therapeutics Corp0.00-2.39bn2.91bn37.00--1.91-----76.74-76.740.0041.390.00----0.00-92.78-29.19-99.33-30.02-------597.359.84--0.2301---100.00--11.50--135.50--
Atect Corp3.20bn114.29m3.00bn96.0026.191.436.520.938825.8525.85723.76474.920.57133.226.8533,330,020.002.042.032.832.7844.6847.693.573.840.7119--0.54629.40-4.032.10-6.3714.01-23.310.00
Muromachi Chemicals Inc6.12bn216.69m3.03bn205.0013.841.408.630.495153.4553.451,503.34527.871.203.833.7529,862,370.004.23--6.84--28.31--3.54--1.4526.200.4483--10.74---43.83------
Ribomic Inc62.64m-979.09m3.12bn25.00--0.8566--49.86-27.45-27.451.76100.390.0144--1.222,505,440.00-22.56-32.10-24.05-33.30-----1,563.14-1,688.5018.53--0.00---18.470.38091.88--10.04--
D.Western Therapeutics Institute Inc428.36m-812.41m3.53bn21.00--2.76--8.25-25.45-25.4513.4839.830.16070.43892.9820,398,290.00-31.09-13.06-33.75-14.3691.4494.29-193.39-72.5110.57--0.4089---4.407.90-89.07--7.08--
Kringle Pharma Inc70.58m-865.79m3.72bn13.00--1.53--52.67-158.59-158.5912.88374.930.024--0.73085,428,846.00-29.38-19.00-30.70-20.23-----1,226.76-156.5126.45-1,190.330.00---82.33---157.41------
Human Metabolome Technologies Inc1.32bn282.64m3.82bn57.0013.492.1610.462.8947.8347.83223.67299.170.630214.234.7423,186,330.0013.48--16.73--65.03--21.39--4.27151.900.1103--6.21--6.71------
FunPep Co Ltd530.00k-933.42m3.82bn15.00--1.55--7,213.76-40.11-40.110.022594.970.0002----35,333.33-34.04-27.10-35.68-28.75-----176,116.20-815.8225.95-1,765.730.00---50.33-72.8020.39---13.14--
Kubota Pharmaceutical Holdings Co Ltd39.89m-1.49bn4.00bn12.00--1.50--100.21-26.80-26.800.717547.210.01070.531714.773,323,917.00-40.06-36.51-43.86-39.4770.48---3,734.55-13,528.8710.01--0.0512--383.24--26.11--24.38--
OncoTherapy Science, Inc.901.22m-1.19bn4.00bn60.00--5.97--4.44-5.77-5.774.363.010.75895.3115.7415,020,330.00-100.44-50.21-132.58-55.41-9.03---132.35-331.973.29-258.180.00---1.6339.9756.50---57.92--
Perseus Proteomics Inc96.22m-1.12bn4.05bn24.00--2.53--42.09-95.57-95.578.18131.490.04241.8211.224,009,083.00-49.52-33.51-51.65-34.9589.0193.09-1,168.66-470.6317.58--0.00--30.96-20.89-31.38--228.18--
BrightPath Biotherapeutics Co Ltd118.00k-1.21bn4.22bn32.00--5.03--35,774.55-19.27-19.270.001911.920.00007--0.04233,687.50-71.34-42.65-89.42-44.49-433.0557.16-1,028,827.00-4,430.66---875.450.3929---65.73-56.89-0.0971---56.39--
Immuno-Biological Laboratories Co., Ltd.788.12m-192.71m4.28bn60.00--3.90--5.44-20.69-20.6984.62118.020.51440.87883.7813,135,280.00-12.58-15.11-14.85-17.6162.0656.66-24.45-50.043.490.4940.1774--22.710.9405-11.97------
Renascience Inc191.32m-331.66m4.44bn3.00--2.70--23.19-26.09-26.0915.05129.220.0851----63,772,000.00-14.74---15.49--85.75---173.36------0.1782---27.84---32.05------
MEDRx Co Ltd29.53m-932.90m4.60bn22.00--2.25--155.89-27.24-27.240.849250.170.01710.26061.221,342,455.00-54.07-58.15-58.45-62.2391.8795.70-3,158.72-1,526.1717.75--0.00---50.3528.6016.04---55.29--
Solasia Pharma KK617.00m-1.11bn5.18bn24.00--2.50--8.40-6.61-6.613.6710.780.23014.101.9325,708,330.00-41.51-48.57-47.74-58.8354.7871.01-180.39-300.892.91--0.031---43.5014.1856.36------
Data as of May 02 2024. Currency figures normalised to Human Metabolome Technologies Inc's reporting currency: Japanese Yen JPY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.